-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the news that the drug for the treatment of "sausage mouth" rare diseases has entered the medical insurance once became popular, which caused widespread concern and discussion in the industry
.
It is reported that the disease is called hereditary angioedema (HAE), is a rare autosomal dominant genetic disease, the global prevalence of only 1 in 50,000
.
Its main attack is characterized by recurrent localized subcutaneous or mucosal edema, often involving the face, limbs, genital area, gastrointestinal tract, and larynx
.
When edema developed in the larynx, the progression was rapid, with a mean time from onset of edema to asphyxia of 4.
6 hours
.
According to statistics, nearly 60% of HAE patients in China have experienced laryngeal edema, which brings serious threat to life
.
On December 3, 2021, the National Medical Insurance Administration announced the negotiation results of the 2021 medical insurance catalogue.
Feizeyou (ictibant acetate injection), which is a drug for HAE emergency attacks, was also included, and it will be officially implemented from January 1, 2022
.
According to media reports, the Second Hospital of Zhejiang University issued the first national prescription for "icibant acetate injection" after it was included in the medical insurance.
Improve patients' quality of life
.
After the news was released, netizens expressed their "really grateful to the Medical Insurance Bureau" and "hope that medical insurance can benefit more patients with rare diseases and chronic diseases"
.
Rare disease is a disease with a small number of patients, such as people familiar with people such as "gradual freezing" (amyotrophic lateral sclerosis patients), "glass man" (hemophilia), "porcelain doll" (adult).
Osteoarthritis patients), "Puppet Man" (multiple sclerosis patients), "flabby children" (spinal muscular atrophy patients) and so on belong to the field of rare diseases
.
At present, there are about 20 million patients with various rare diseases in China, with more than 200,000 new patients every year
.
These groups generally have the problem of not being able to buy and use medicines
.
In order to solve the problem of difficult drug use for rare diseases, relevant departments in my country have been actively carrying out actions to speed up making rare diseases no longer "rare"
.
For example, the Opinions on Reforming the Review and Approval System for Drugs and Medical Devices issued in August 2015 required that the review and approval of innovative drugs for rare diseases and other diseases be accelerated; Conditionally approved for marketing, as of now, 26 rare disease drugs have been approved for marketing through the special channel for overseas new drugs urgently needed in clinical practice
.
On January 6, 2022, the Center for Drug Evaluation of the State Food and Drug Administration issued the "Technical Guiding Principles for Clinical Research and Development of Drugs for Rare Diseases" (hereinafter referred to as the "Principles").
With the company's enthusiasm for research and development in the field of rare diseases, there may be more and better rare disease drugs on the market in the future, bringing good news to the majority of rare disease patients
.
In order to solve the problem of expensive drugs for rare disease patients, since its establishment in 2018, the National Medical Security Administration has dynamically adjusted the medical insurance drug list once a year, and many rare disease drugs have also been included
.
According to information at the 2021 China Rare Disease Conference held on December 18, 2021, as of now, more than 60 rare disease drugs have been approved for marketing in China, of which more than 40 have been included in the medical insurance catalog
.
In the national medical insurance negotiation in 2021, 7 drugs for rare diseases will be included, and the price will drop by an average of 65%.
Among them, the price of Nosinason Sodium Injection has been reduced from 550,000 injections to 30,000 yuan per injection, greatly reducing the price.
Medication burden of patients
.
.
It is reported that the disease is called hereditary angioedema (HAE), is a rare autosomal dominant genetic disease, the global prevalence of only 1 in 50,000
.
Its main attack is characterized by recurrent localized subcutaneous or mucosal edema, often involving the face, limbs, genital area, gastrointestinal tract, and larynx
.
When edema developed in the larynx, the progression was rapid, with a mean time from onset of edema to asphyxia of 4.
6 hours
.
According to statistics, nearly 60% of HAE patients in China have experienced laryngeal edema, which brings serious threat to life
.
On December 3, 2021, the National Medical Insurance Administration announced the negotiation results of the 2021 medical insurance catalogue.
Feizeyou (ictibant acetate injection), which is a drug for HAE emergency attacks, was also included, and it will be officially implemented from January 1, 2022
.
According to media reports, the Second Hospital of Zhejiang University issued the first national prescription for "icibant acetate injection" after it was included in the medical insurance.
Improve patients' quality of life
.
After the news was released, netizens expressed their "really grateful to the Medical Insurance Bureau" and "hope that medical insurance can benefit more patients with rare diseases and chronic diseases"
.
Rare disease is a disease with a small number of patients, such as people familiar with people such as "gradual freezing" (amyotrophic lateral sclerosis patients), "glass man" (hemophilia), "porcelain doll" (adult).
Osteoarthritis patients), "Puppet Man" (multiple sclerosis patients), "flabby children" (spinal muscular atrophy patients) and so on belong to the field of rare diseases
.
At present, there are about 20 million patients with various rare diseases in China, with more than 200,000 new patients every year
.
These groups generally have the problem of not being able to buy and use medicines
.
In order to solve the problem of difficult drug use for rare diseases, relevant departments in my country have been actively carrying out actions to speed up making rare diseases no longer "rare"
.
For example, the Opinions on Reforming the Review and Approval System for Drugs and Medical Devices issued in August 2015 required that the review and approval of innovative drugs for rare diseases and other diseases be accelerated; Conditionally approved for marketing, as of now, 26 rare disease drugs have been approved for marketing through the special channel for overseas new drugs urgently needed in clinical practice
.
On January 6, 2022, the Center for Drug Evaluation of the State Food and Drug Administration issued the "Technical Guiding Principles for Clinical Research and Development of Drugs for Rare Diseases" (hereinafter referred to as the "Principles").
With the company's enthusiasm for research and development in the field of rare diseases, there may be more and better rare disease drugs on the market in the future, bringing good news to the majority of rare disease patients
.
In order to solve the problem of expensive drugs for rare disease patients, since its establishment in 2018, the National Medical Security Administration has dynamically adjusted the medical insurance drug list once a year, and many rare disease drugs have also been included
.
According to information at the 2021 China Rare Disease Conference held on December 18, 2021, as of now, more than 60 rare disease drugs have been approved for marketing in China, of which more than 40 have been included in the medical insurance catalog
.
In the national medical insurance negotiation in 2021, 7 drugs for rare diseases will be included, and the price will drop by an average of 65%.
Among them, the price of Nosinason Sodium Injection has been reduced from 550,000 injections to 30,000 yuan per injection, greatly reducing the price.
Medication burden of patients
.
